TB-500 in 2026 Q2: what changed

Between 1 April and 30 June 2026, TB-500 picked up a United States regulatory date and one new registered trial, and neither of them tested the thing most buyers want it for. On 16 April 2026 the Food and Drug Administration published a Federal Register notice putting TB-500 (free base and acetate) on the agenda of its Pharmacy Compounding Advisory Committee for 23 July 2026, with the sole nominated use recorded as wound healing.^[1] This digest covers what moved inside the quarter and, more usefully, what did not.

A July date and a one line nomination

The notice was filed under docket FDA-2025-N-6895 and set a two day agenda for seven peptide bulk drug substances. BPC-157, KPV, TB-500 and MOTs-C were scheduled for 23 July 2026. Emideltide, Semax and Epitalon were scheduled for 24 July.^[1] The public comment docket was set to close on 22 July 2026, so most of the comment window sat inside the quarter.^[1]

The nominated use matters as much as the date. The agency's own agenda records the only use it evaluated for TB-500 as wound healing.^[9] That is a good deal narrower than the tendon, ligament and general injury recovery framing that drives grey market demand, and a committee vote on wound healing would not speak to those uses. Nomination to the 503A bulks list is a request to make a substance eligible for pharmacy compounding, not an application for a marketing authorisation. FDA also states plainly that its advisory committees "make non-binding recommendations to the FDA, which generally follows the recommendations but is not legally bound to do so."^[9]

What FDA says it does not have

The agency's safety page for compounding bulk substances, content current as of 22 April 2026, carries an entry for the exact sequence sold as TB-500. It states that compounded drugs containing thymosin Beta-4, Fragment (LKKTETQ) may pose a risk of immunogenicity for certain routes of administration because of potential aggregation and peptide-related impurities.^[2] Immunogenicity here means the body mounting an immune response against the injected material. Aggregation means peptide molecules clumping together, which is one of the things that raises that risk.

Compounded drugs containing thymosin Beta-4, Fragment (LKKTETQ) may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation as well as peptide-related impurities.

The same page records that FDA has not identified human exposure data for the substance and lacks safety information about potential harm if it is given to people.^[2] That is the line to sit with. A regulator scheduled a review of a peptide it says it has no human exposure data for, which tells you how thin the file is rather than how promising the molecule looks.

One new trial registration, and it is not the fragment

The quarter produced exactly one new entry for this molecule in the main international registry. On 30 April 2026 Beijing Northland Biotech submitted a Phase 2 study of recombinant human thymosin beta 4 injection (NL005) in patients with acute myocardial infarction, posted on 14 May 2026 as NCT07586865.^[3] It plans 189 participants at multiple centres in China, started on 18 May 2026, and takes absolute and relative myocardial infarct size at day 90 as its primary outcome measures.^[3]

Read the molecule carefully. NL005 is recombinant full length thymosin beta 4, given for heart attack, and not the AC-LKKTETQ heptapeptide that vendors sell as TB-500 for soft tissue recovery. That distinction is the one our TB-500 reference page keeps coming back to, because the published literature and the marketing do not use the same vocabulary.

The one registered trial of the fragment itself was posted just before the quarter opened. NCT07487363, sponsored by Hudson Biotech, is a Phase 1/2 placebo controlled study of TB-500 (thymosin beta 4 17-23 fragment) in 80 adults with stable atherosclerotic cardiovascular disease in China. It was first posted on 23 March 2026 and was recruiting across the quarter, and a registry query for TB-500 returns a total count of one.^[4] Its endpoints are cardiovascular biomarkers and vascular function, not tendon or ligament repair.

The published literature moved sideways

A PubMed query for thymosin beta 4 or TB-500 in the title or abstract, restricted to a publication date between 1 April and 30 June 2026, returns six records.^[5] Not one of them is a human trial of TB-500 for injury recovery. Two are proteomics papers in which thymosin beta 4 turns up as a measured protein rather than as a treatment.

The closest thing to a therapeutic result in the window is a mouse experiment. In the 1 June 2026 issue of Investigative Ophthalmology and Visual Science, Ebrahim and colleagues reported that adjunctive Tβ4 with ciprofloxacin "markedly improved visual acuity and contrast sensitivity and significantly enhanced corneal sensitivity and nerve regeneration" in C57BL/6 mice with Pseudomonas aeruginosa keratitis, restoring nerve density to levels comparable with uninfected controls.^[6] That is a topical eye treatment in mice, sitting in the same ophthalmology lineage that produced the only Western standard human trial data on this molecule.

The quarter's one review is candid about the state of the file. Writing in Integrative Medicine in April 2026, Mazza surveyed peptide therapies in thyroid health, thymosin beta-4 among them, and noted that the available evidence consists "primarily of preclinical investigations, mechanistic studies, and early exploratory clinical reports."^[7] The closing judgement was that peptide therapeutics "represent a developing research domain whose relevance to thyroid care remains to be established through rigorous investigation."^[7]

What did not change

TB-500 held no marketing authorisation in the European Union, the United Kingdom or the United States on 1 April 2026, and it held none on 30 June. Its anti-doping status also stayed where it has been since 1 January 2018, when thymosin-β4 and its derivatives, TB-500 given as the example, were added as prohibited growth factors under section S2.3 of the Prohibited List.^[8] Nothing in the quarter touched either of those two facts, and neither is likely to move before the committee reports.

What we do not yet know

We do not know how the committee will vote on 23 July 2026, and the quarter gave no basis for guessing. We do not know the human safety profile of injected TB-500, because the agency says it has not identified human exposure data and no completed trial fills that gap.^[2] We do not know whether the cardiovascular work now registered in China will report anything that transfers to soft tissue injury, because neither study is measuring it.^[3]

The honest reading of Q2 2026 is that TB-500 gained a calendar entry and a heart trial for a different molecule, while the injury recovery case that actually sells it stayed exactly where it was. If you are considering it, that gap should weigh more than a scheduled meeting. Take the question to a clinician who knows your history rather than to a seller. For the standing summary, start with our TB-500 page and the United States regulation hub.